Display options
Cite
Compter I, Eekers DBP, Hoeben A, et al. Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy. 2020;17(9):2604-2612doi: 10.1080/15548627.2020.1816343.
Compter, I., Eekers, D. B. P., Hoeben, A., Rouschop, K. M. A., Reymen, B., Ackermans, L., Beckervordersantforth, J., Bauer, N. J. C., Anten, M. M., Wesseling, P., Postma, A. A., De Ruysscher, D., & Lambin, P. (2021). Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy, 17(9), 2604-2612. https://doi.org/10.1080/15548627.2020.1816343
Compter, Inge, et al. "Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial." Autophagy vol. 17,9 (2021): 2604-2612. doi: https://doi.org/10.1080/15548627.2020.1816343
Compter I, Eekers DBP, Hoeben A, Rouschop KMA, Reymen B, Ackermans L, Beckervordersantforth J, Bauer NJC, Anten MM, Wesseling P, Postma AA, De Ruysscher D, Lambin P. Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial. Autophagy. 2021 Sep;17(9):2604-2612. doi: 10.1080/15548627.2020.1816343. Epub 2020 Sep 20. PMID: 32866424; PMCID: PMC8496728.
Copy Download .nbib Format: NLM
Share it on

Autophagy. 2021 Sep;17(9):2604-2612. doi: 10.1080/15548627.2020.1816343. Epub 2020 Sep 20.

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.

Autophagy

Inge Compter, Danielle B P Eekers, Ann Hoeben, Kasper M A Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J C Bauer, Monique M Anten, Pieter Wesseling, Alida A Postma, Dirk De Ruysscher, Philippe Lambin

Affiliations

  1. Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  2. Department of Medical Oncology, GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  3. Department of Radiotherapy, GROW School for Oncology, Maastricht University, Maastricht, The Netherlands.
  4. Department of Neurosurgery, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  5. Department of Pathology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  6. Department of Ophthalmology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  7. Department of Neurology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
  8. Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands.
  9. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  10. Department of Radiology and Nuclear Medicine, School for Mental Health and Sciences, Maastricht University Medical Centre+, Maastricht University Medical Center, Maastricht, The Netherlands.
  11. The D-Lab & the M-lab, Dpt of Precision Medicine, GROW - School for Oncology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

PMID: 32866424 PMCID: PMC8496728 DOI: 10.1080/15548627.2020.1816343

Abstract

Treatment of glioblastoma xenografts with chloroquine results in macroautophagy/autophagy inhibition, resulting in a reduction of tumor hypoxia and sensitization to radiation. Preclinical data show that

Keywords: Autophagy; brain tumor; chloroquine; glioblastoma; radiotherapy; temozolomide

References

  1. Autophagy. 2014 Aug;10(8):1359-68 - PubMed
  2. J Natl Cancer Inst. 2009 May 20;101(10):708-20 - PubMed
  3. Radiother Oncol. 2009 Sep;92(3):399-404 - PubMed
  4. Oncol Lett. 2017 Jul;14(1):322-328 - PubMed
  5. Cancer Chemother Pharmacol. 2017 Nov;80(5):1005-1012 - PubMed
  6. Cancer Lett. 2015 May 1;360(2):195-204 - PubMed
  7. Radiother Oncol. 2009 Sep;92(3):411-6 - PubMed
  8. Front Oncol. 2018 Aug 27;8:335 - PubMed
  9. J Clin Invest. 2010 Jan;120(1):127-41 - PubMed
  10. Cell. 2013 Oct 10;155(2):462-77 - PubMed
  11. Eur J Pharmacol. 2016 Jan 15;771:139-44 - PubMed
  12. Autophagy. 2018;14(2):283-295 - PubMed
  13. Ann Intern Med. 2006 Mar 7;144(5):337-43 - PubMed
  14. EMBO J. 2006 Feb 22;25(4):683-92 - PubMed
  15. Neuro Oncol. 2015 Jun;17(6):776-83 - PubMed
  16. Cancer Lett. 2015 Mar 28;358(2):220-231 - PubMed
  17. PLoS One. 2012;7(6):e38706 - PubMed
  18. J Neurosurg. 2003 Feb;98(2):378-84 - PubMed
  19. Breast Cancer Res Treat. 2019 Nov;178(2):327-335 - PubMed
  20. Cell Death Differ. 2005 Nov;12 Suppl 2:1535-41 - PubMed
  21. Lancet Infect Dis. 2007 Aug;7(8):549-58 - PubMed
  22. Neuro Oncol. 2014 Oct;16 Suppl 8:viii1-6 - PubMed
  23. Lancet Oncol. 2009 May;10(5):459-66 - PubMed
  24. Cancer Res. 2001 Jan 15;61(2):439-44 - PubMed
  25. Science. 2014 Jun 20;344(6190):1396-401 - PubMed
  26. J Pharm Pharmacol. 1982 Nov;34(11):733-5 - PubMed
  27. BMC Neurol. 2016 Sep 20;16(1):178 - PubMed
  28. Autophagy. 2012 Feb 1;8(2):200-12 - PubMed
  29. Anticancer Drugs. 2013 Jan;24(1):14-9 - PubMed
  30. Lancet Oncol. 2017 Jun;18(6):e315-e329 - PubMed
  31. Strahlenther Onkol. 2014 Oct;190(10):957-61 - PubMed
  32. Neurosurg Focus. 2014 Dec;37(6):E12 - PubMed
  33. Ophthalmology. 2011 Feb;118(2):415-22 - PubMed
  34. Cell Death Differ. 2004 Apr;11(4):448-57 - PubMed
  35. Nat Med. 2007 Sep;13(9):1050-9 - PubMed
  36. Cell Death Differ. 2014 Jan;21(1):92-9 - PubMed
  37. Int J Oncol. 2005 May;26(5):1401-10 - PubMed
  38. Cancer Biol Ther. 2009 Apr;8(8):730-8 - PubMed
  39. Mol Biol Cell. 2004 Mar;15(3):1101-11 - PubMed
  40. Ther Drug Monit. 1989;11(4):369-79 - PubMed
  41. PLoS One. 2012;7(10):e47357 - PubMed
  42. Cancer Res. 2003 Oct 15;63(20):6962-70 - PubMed
  43. Cancer Cell. 2014 Aug 11;26(2):190-206 - PubMed
  44. Oncoimmunology. 2014 Jul 03;3(7):e944047 - PubMed
  45. Surg Neurol. 2007 Apr;67(4):388-91 - PubMed
  46. Cell Death Dis. 2013 Oct 10;4:e838 - PubMed
  47. J Neurooncol. 2015 Mar;122(1):11-20 - PubMed
  48. Eur J Clin Pharmacol. 1992;42(4):429-33 - PubMed
  49. Radiother Oncol. 2007 Jun;83(3):333-9 - PubMed
  50. Drug Resist Updat. 2004 Feb;7(1):25-40 - PubMed
  51. Lancet Infect Dis. 2003 Nov;3(11):722-7 - PubMed
  52. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed

Publication Types